Barbara Greising Joins Clinical Data's PGxHealth as Division Vice President.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that it has appointed Barbara Greising, most recently with Medco Health Solutions, Inc., to the position of Vice President, PGxHealth, effective March 27, 2006.

Greising will be working with Clinical Data's executive management team on PGxHealth's overall strategy and product development including the introduction and management of current and new Therapeutic Diagnostics(TM). Her responsibilities also include the development and management of the infrastructure required to support the division's expanding catalog of tests, management of partnership opportunities focused on both accelerating marker development and adoption of PGxHealth's products and services, and strategies and activities relating to payers, providers and consumers. She will report to Drew Fromkin, Clinical Data's Executive Vice President.

At Medco, the leading PBM (prescription benefit management company), Greising was most recently Vice President for Sales, Marketing and Client Services of Medco's specialty pharma division, Specialty Solutions. In this role, Greising oversaw the development and execution of customer sales and retention strategies as well as ongoing client, member and physician services. This role also included responsibility for overall client relationships (including financial, clinical and operational commitments) and any related client specific strategies for Medco's specialty pharma business. Specialty Solutions' clients included payers, employers, unions, benefit consultants and major provider groups.

Commenting on Barbara Greising's new position, Drew Fromkin said, "We are delighted Barbara has decided to join our team. She has a strong history of delivering in high growth environments, and we will benefit greatly from her extensive understanding of care management programs, payer and provider requirements as well as the dynamics around the introduction of novel treatments into established care settings. As Clinical Data continues to introduce Therapeutic Diagnostics to optimize the use of therapies in specific patient populations, Barbara's knowledge and experience will have a significant impact across the division's activities and strategy."

Greising said, "PGxHealth offers unique opportunities as the division defines itself and executes on its business plan. PGxHealth, a pioneer in its field, already has a strong record of developing and delivering clinical diagnostics and discovering important genetic markers. I am proud to be joining a team dedicated to improving patient care and reducing total health care costs through the use of cutting-edge technology. I am looking forward to working with Drew and the entire PGxHealth team."

Greising also served as Senior Director at Medco responsible for the overall development, implementation and ongoing management of Medco's health management product portfolio. Greising received The Women in Industry (TWIN) Award while in this position. Greising subsequently was promoted to serve as a National Account Executive in 2000 for several large national accounts representing over $1 billion in annual drug spend. Prior to joining Medco in 1996, Greising was an equity partner at Cardiovascular Outcome Management. She has more than 17 years experience in the health care industry including as a former Blue Cross Blue Shield product development professional. Greising received a B.A. from the State University of New York at Albany and an M.B.A. from the Lubin Graduate School of Business at Pace University.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care. Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets acquired from Genaissance Pharmaceuticals in the areas of genomics-based, clinical diagnostics, therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development, including pharmacovigilance requirements post launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-KSB for the fiscal year ended March 31, 2005, and fiscal 2005 and 2006 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com